Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AB1010 (masitinib) is a tyrosine kinase inhibitor, small molecule drug. It is being evaluated in phase 3 clinical studies in combination with Rilutek (riluzole) for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2024
Details:
AB1010 (masitinib), is one of the most promising drugs in ALS that has just been submitted to the EMA conditional approval process. Masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
AB1010 (masitinib), is one of the most promising drugs in ALS that has just been submitted to the EMA conditional approval process. Masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
AB1010 (masitinib) is a tyrosine kinase inhibitor, emphasizes the neuro-inflammatory activity of ALS by targeting macrophages, mast cells, and microglia cells. It downregulates the proinflammatory cytokines, indirectly reduces inflammation, and induces neuroprotection.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
The proceeds will be used to fund the development of AB1010 (masitinib) for the treatment of amyotrophic lateral sclerosis and the development of the microtubule destabilizer agents (MDA) platform, with the clinical development of AB8939 in refractory acute myeloid leukemia.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $16.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 24, 2023
Details:
AB1010 (masitinib), a tyrosine kinase inhibitor, emphasizes the neuro-inflammatory activity of ALS by targeting macrophages, mast cells, and microglia cells. It downregulates the proinflammatory cytokines, indirectly reduces inflammation, and induces neuroprotection.
Lead Product(s): Masitinib Mesylate,Riluzole
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
AB1010 (masitinib), is one of the most promising drugs in ALS that has just been submitted to the EMA conditional approval process. Masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
AB8939 is a new synthetic microtubule-destabilizing drug, having broad anticancer activity, with a notable advantage over standard chemotherapies that target microtubules of being able to overcome Pgp and MPO mediated drug resistance.
Lead Product(s): AB8939,Azacitidine
Therapeutic Area: Oncology Product Name: AB8939
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
AB1010 (masitinib), targets microglia and mast cells, which are two cells of the innate immune system associated with the pathology of progressive MS. The mechanism of action of masitinib is different from and potentially complementary to other tyrosine kinase inhibitors.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2022
Details:
AB1010 (masitinib) is an orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity. It can be developed for number of conditions in oncology, inflammatory diseases, and in CNS diseases.
Lead Product(s): Masitinib Mesylate
Therapeutic Area: Neurology Product Name: AB1010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022